Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Johnson & Johnson 4Q Results | Contract Pharma

What are you searching for?

Sign in
Financial News

Johnson & Johnson 4Q Results

Innovative Medicine sales were $14.3 billion in the quarter, up 4%.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson

4Q Revenues: $22.5 billion (+5%)

4Q Earnings: $3.4 billion (-17%)

FY Revenues: $88.8 billion (+4%)

FY Earnings: $14.1 billion (+6%)

Comments: Innovative Medicine sales were $14.3 billion in the quarter, up 4%, and $57.0 billion for the year, up 4%. Growth in the quarter was driven primarily by DARZALEX up 21% to $3.1 billion, ERLEADA up 21% to $784 million, TREMFYA in Immunology, up 4%to $949 million, and SPRAVATO in Neuroscience, up 45% to $297 million. Growth was partially offset by STELARA in Immunology, down 15% to $2.3 billion. Remeicade sales were down 17% to $359 million, in the quarter. Infectious diseases sales were down 9% to $774 million. INVEGA SUSTENNA sales were $1.06 billion, up 5%. IMBRUVICA sales were down 7% to $731 million. XARELTO sales were up 29% to $676 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics